Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 571 matching drugs for EZH2 — including drugs targeting any of its 195 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
durvalumab, tazemetostat EZH2 Direct 1
tazemetostat EZH2 Direct yes 0
sunitinib PDGFRB SSL via PDGFRB yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRB SSL via PDGFRB 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRB SSL via PDGFRB 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK4 SSL via CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PDGFRB SSL via PDGFRB 3
afatinib ERBB2 SSL via ERBB2 yes 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus MTOR SSL via MTOR 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan TOP1 SSL via TOP1 3
lurbinectedin, irinotecan TOP1 SSL via TOP1 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone PPARG SSL via PPARG 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
abemaciclib CDK4 SSL via CDK4 yes 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
alendronate, etidronate, ibandronate, risedronate, raloxifene ESR1 SSL via ESR1 2
alvocidib, paclitaxel CDK4 SSL via CDK4 2
alvocidib, paclitaxel CDK5 SSL via CDK5 2
apatinib, irinotecan TOP1 SSL via TOP1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan TOP1 SSL via TOP1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine TOP1 SSL via TOP1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PDGFRB SSL via PDGFRB 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK4 SSL via CDK4 2
bryostatin 1, paclitaxel CCND1 SSL via CCND1 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery TOP1 SSL via TOP1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study MTOR SSL via MTOR 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK4 SSL via CDK4 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 SSL via ERBB2 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ESR1 SSL via ESR1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PDGFRB SSL via PDGFRB 2
everolimus MTOR SSL via MTOR yes 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC2 SSL via HDAC2 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC8 SSL via HDAC8 2
gefitinib, fulvestrant, erlotinib ESR1 SSL via ESR1 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide TOP1 SSL via TOP1 2
irinotecan, capecitabine TOP1 SSL via TOP1 2
irinotecan, docetaxel TOP1 SSL via TOP1 2
lapatinib ERBB2 SSL via ERBB2 yes 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab TOP1 SSL via TOP1 2
nintedanib PDGFRB SSL via PDGFRB yes 2
nintedanib, pembrolizumab PDGFRB SSL via PDGFRB 2
olaparib PARP3 SSL via PARP3 2
palbociclib CDK4 SSL via CDK4 yes 2
pazopanib PDGFRB SSL via PDGFRB yes 2
pembrolizumab, guadecitabine, mocetinostat HDAC2 SSL via HDAC2 2
pembrolizumab, paclitaxel, docetaxel, irinotecan TOP1 SSL via TOP1 2
pharmacological study, romidepsin HDAC2 SSL via HDAC2 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies ERBB2 SSL via ERBB2 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib PDGFRB SSL via PDGFRB yes 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
regorafenib, laboratory biomarker analysis PDGFRB SSL via PDGFRB 2
rubitecan TOP1 SSL via TOP1 2
sacituzumab govitecan TOP1 SSL via TOP1 yes 2
sorafenib, administered orally, ct/mri PDGFRB SSL via PDGFRB 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel ESR1 SSL via ESR1 2
temsirolimus MTOR SSL via MTOR 2
temsirolimus, laboratory biomarker analysis MTOR SSL via MTOR 2
topotecan TOP1 SSL via TOP1 yes 2
trastuzumab ERBB2 SSL via ERBB2 yes 2
trastuzumab deruxtecan TOP1 SSL via TOP1 yes 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy ERBB2 SSL via ERBB2 2
trastuzumab, tipifarnib ERBB2 SSL via ERBB2 2
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography PARP3 SSL via PARP3 1
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks ERBB2 SSL via ERBB2 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC8 SSL via HDAC8 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC8 SSL via HDAC8 1
5 fluorouracil, leucovorin, irinotecan, oxaliplatin TOP1 SSL via TOP1 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy ERBB2 SSL via ERBB2 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan TOP1 SSL via TOP1 1
abemaciclib, abemaciclib CDK4 SSL via CDK4 1
abemaciclib, bevacizumab CDK4 SSL via CDK4 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf CDK4 SSL via CDK4 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf TOP1 SSL via TOP1 1
abemaciclib, ly3023414, gemcitabine, capecitabine CDK4 SSL via CDK4 1
abemaciclib, ly3214996 CDK4 SSL via CDK4 1
abemaciclib, surgery CDK4 SSL via CDK4 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy HDAC2 SSL via HDAC2 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy PPARG SSL via PPARG 1
adriamycin, cyclophosphamide, vindesine, valproic acid HDAC2 SSL via HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid PPARG SSL via PPARG 1
aee788, everolimus MTOR SSL via MTOR 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ABL1 SSL via ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CDK4 SSL via CDK4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib MTOR SSL via MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PARP3 SSL via PARP3 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PDGFRB SSL via PDGFRB 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.